Arabinopyranosyl-N-methyl-N-nitrosourea
Soviet-developed alkylating nitrosourea for melanoma treatment.
Last updated
Arabinopyranosyl-N-methyl-N-nitrosourea, also known as Aranose (Араноза), is a cytostatic anticancer chemotherapeutic drug of an alkylating type. Chemically a nitrosourea derivative, it was developed in the Soviet Union in the 1970s. Its developers claimed advantages over other nitrosoureas, including relatively low hematological toxicity and a wider therapeutic index, allowing for outpatient administration.
Quick Facts
- Field
- Oncology, Chemotherapy
- Nationality
- Soviet Union (Russia)
- Type
- Nitrosourea derivative
- Developed
- 1970s
Facts from the source article.
Background
Arabinopyranosyl-N-methyl-N-nitrosourea was first synthesized in the late 1970s in the Laboratory of Organic Synthesis of the Soviet Cancer Research Institute, which belonged to the Academy of Medical Sciences of the USSR. Its first clinical trials in the USSR were conducted in the late 1980s, confirming potential clinical efficacy in melanoma and better relative safety and improved tolerability over other nitrosourea antineoplastic compounds available at that time. In 1996, the compound obtained regulatory approval from the Russian Pharmacologic Committee for use in melanoma under the trade name Aranoza.
More in Soviet inventions
Sources
Compiled from Wikipedia and the sources listed below. Text from Wikipedia is available under CC BY-SA 4.0; this entry is adapted from it.
- Wikipedia: Arabinopyranosyl-N-methyl-N-nitrosourea (CC BY-SA 4.0).
Spotted an error? Know more?
Reader corrections go straight into our review queue. Suggest an edit · How this site is sourced